Medical College of Wisconsin
CTSIResearch InformaticsREDCap

High-Dose Intravitreal Topotecan for Retinoblastoma With Subretinal Seeds: A Well-Tolerated and Efficacious Approach. J Pediatr Hematol Oncol 2026 Jul 01;48(5):242-245

Date

06/09/2026

Pubmed ID

42263182

DOI

10.1097/MPH.0000000000003221

Scopus ID

2-s2.0-105043501104 (requires institutional sign-in at Scopus site)

Abstract

BACKGROUND: High-dose intravitreal topotecan (90 μg) has emerged as a promising treatment option for refractory or recurrent retinoblastoma with active tumor and subretinal seeds, offering localized disease control while minimizing systemic toxicity.

OBSERVATIONS: In this 5-patient case series, tumor regression was achieved in 4 cases without significant adverse effects. One patient required enucleation due to disease progression. Timely administration and consistent follow-up were identified as key factors influencing treatment outcomes.

CONCLUSIONS: High-dose intravitreal topotecan demonstrates meaningful therapeutic potential in achieving localized tumor control with an acceptable safety profile, supporting further investigation into its role in managing refractory retinoblastoma.

Author List

Palia R, Alvarado W, Becktell K, Ramasubramanian A, Liberio N

Authors

Kerri Becktell MD Associate Professor in the Pediatrics department at Medical College of Wisconsin
Aparna Ramasubramanian MBBS Chief, Professor in the Ophthalmology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Humans
Intravitreal Injections
Retinal Neoplasms
Retinoblastoma
Topoisomerase I Inhibitors
Topotecan